Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Active Controlled, Multi-center Phase 3 Clinical Study to Compare the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection With Chidamide in Patients With Relapsed/Refractory PTCL.

NCT04668690 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT04668690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04668690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Active Controlled, Multi-center Phase 3 Clinical Study to Compare the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection With Chidamide in Patients With Relapsed/Refractory PTCL.
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 13, 2021
Completion date
December 30, 2028
Enrollment
193 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma